{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:33:58Z","timestamp":1790505238251,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Capital's Funds for Health Improvement and Research","award":["2018-2-4031"],"award-info":[{"award-number":["2018-2-4031"]}]},{"name":"National Key Research and Development Program of China","award":["2017YFC0908800"],"award-info":[{"award-number":["2017YFC0908800"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Renin\u2013angiotensin\u2013aldosterone-system inhibitors markedly play an active role in the primary prevention of atrial fibrillation (AF), but the impact of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) on the mortality of patients with AF remains unclear. This study aimed to examine the relationship between treatment with ACEIs or ARBs and mortality in emergency department (ED) patients with AF and hypertension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter study enrolled 2016 ED patients from September 2008 to April 2011; 1110 patients with AF and hypertension were analyzed. Patients were grouped according to whether they were treated with ACEI\/ARB or not and completed a 1-year follow-up to evaluate outcomes including all-cause death, cardiovascular death, stroke, and major adverse events (MAEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 1110 patients with AF and hypertension, 574 (51.7%) received ACEI\/ARB treatment. During the 1-year follow-up, 169 all-cause deaths (15.2%) and 100 cardiovascular deaths (9.0%) occurred, while 98 strokes (8.8%) and 255 MAEs (23.0%) occurred. According to the multivariate Cox regression analysis, ACEI\/ARB therapy was significantly associated with a reduced risk of all-cause death (HR, 0.605; 95% CI 0.431\u20130.849;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.004). Moreover, ACEI\/ARB therapy was independently associated with a reduced risk of cardiovascular death (HR 0.585; 95% CI 0.372\u20130.921;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.020) and MAEs (HR 0.651, 95% CI 0.496\u20130.855,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002) after adjusting for other risk factors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results revealed that ACEI\/ARB therapy was independently associated with a reduced risk of all-cause death, cardiovascular death, and MAEs in ED patients with AF and hypertension. These results provide evidence for a tertiary preventive treatment for patients with AF and hypertension.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-022-02580-2","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T12:06:33Z","timestamp":1648814793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Impact of renin\u2013angiotensin\u2013aldosterone-system inhibitor drugs on mortality in patients with atrial fibrillation and hypertension"],"prefix":"10.1186","volume":"22","author":[{"given":"Wei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-hui","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"issue":"8","key":"2580_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837\u201347.","journal-title":"Circulation"},{"issue":"9989","key":"2580_CR2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","volume":"386","author":"RB Schnabel","year":"2015","unstructured":"Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA, Magnani JW, Ellinor PT, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet (London, England). 2015;386(9989):154\u201362.","journal-title":"Lancet (London, England)"},{"issue":"10","key":"2580_CR3","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953\u20132041.","journal-title":"J Hypertens"},{"issue":"7","key":"2580_CR4","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1161\/01.CIR.92.7.1954","volume":"92","author":"MC Wijffels","year":"1995","unstructured":"Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92(7):1954\u201368.","journal-title":"Circulation"},{"issue":"2","key":"2580_CR5","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0008-6363(02)00258-4","volume":"54","author":"M Allessie","year":"2002","unstructured":"Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res. 2002;54(2):230\u201346.","journal-title":"Cardiovasc Res"},{"issue":"6","key":"2580_CR6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1161\/01.RES.87.6.440","volume":"87","author":"S Nattel","year":"2000","unstructured":"Nattel S, Li D. Ionic remodeling in the heart: pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ Res. 2000;87(6):440\u20137.","journal-title":"Circ Res"},{"issue":"22","key":"2580_CR7","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.jacc.2014.02.555","volume":"63","author":"S Nattel","year":"2014","unstructured":"Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014;63(22):2335\u201345.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2580_CR8","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jacc.2015.06.1313","volume":"66","author":"MS Dzeshka","year":"2015","unstructured":"Dzeshka MS, Lip GY, Snezhitskiy V, Shantsila E. Cardiac fibrosis in patients with atrial fibrillation: mechanisms and clinical implications. J Am Coll Cardiol. 2015;66(8):943\u201359.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2580_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/HCO.0000000000000027","volume":"29","author":"J Jalife","year":"2014","unstructured":"Jalife J. Mechanisms of persistent atrial fibrillation. Curr Opin Cardiol. 2014;29(1):20\u20137.","journal-title":"Curr Opin Cardiol"},{"key":"2580_CR10","doi-asserted-by":"crossref","unstructured":"Savelieva I, Kakouros N, Kourliouros A, Camm AJ: Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2011, 13(5):610\u2013625.","DOI":"10.1093\/europace\/eur023"},{"issue":"18","key":"2580_CR11","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/eurheartj\/eht507","volume":"35","author":"SC Marott","year":"2014","unstructured":"Marott SC, Nielsen SF, Benn M, Nordestgaard BG. Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. Eur Heart J. 2014;35(18):1205\u201314.","journal-title":"Eur Heart J"},{"issue":"2","key":"2580_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.7326\/0003-4819-152-2-201001190-00005","volume":"152","author":"BA Schaer","year":"2010","unstructured":"Schaer BA, Schneider C, Jick SS, Conen D, Osswald S, Meier CR. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med. 2010;152(2):78\u201384.","journal-title":"Ann Intern Med"},{"key":"2580_CR13","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE et al: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020."},{"issue":"21","key":"2580_CR14","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","volume":"64","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1-76.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2580_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s11883-011-0187-y","volume":"13","author":"J Dubow","year":"2011","unstructured":"Dubow J, Fink ME. Impact of hypertension on stroke. Curr Atheroscler Rep. 2011;13(4):298\u2013305.","journal-title":"Curr Atheroscler Rep"},{"issue":"10050","key":"2580_CR16","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/S0140-6736(16)30968-0","volume":"388","author":"JS Healey","year":"2016","unstructured":"Healey JS, Oldgren J, Ezekowitz M, Zhu J, Pais P, Wang J, Commerford P, Jansky P, Avezum A, Sigamani A, et al. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet (London, England). 2016;388(10050):1161\u20139.","journal-title":"Lancet (London, England)"},{"issue":"38","key":"2580_CR17","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1093\/eurheartj\/ehw233","volume":"37","author":"JP Bassand","year":"2016","unstructured":"Bassand JP, Accetta G, Camm AJ, Cools F, Fitzmaurice DA, Fox KA, Goldhaber SZ, Goto S, Haas S, Hacke W, et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J. 2016;37(38):2882\u20139.","journal-title":"Eur Heart J"},{"issue":"23","key":"2580_CR18","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1016\/j.jacc.2016.09.944","volume":"68","author":"A G\u00f3mez-Outes","year":"2016","unstructured":"G\u00f3mez-Outes A, Lagunar-Ru\u00edz J, Terleira-Fern\u00e1ndez AI, Calvo-Rojas G, Su\u00e1rez-Gea ML, Vargas-Castrill\u00f3n E. Causes of death in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2016;68(23):2508\u201321.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2580_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/HJH.0b013e32834f03bf","volume":"30","author":"AJ Manolis","year":"2012","unstructured":"Manolis AJ, Rosei EA, Coca A, Cifkova R, Erdine SE, Kjeldsen S, Lip GY, Narkiewicz K, Parati G, Redon J, et al. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group \u201cHypertension Arrhythmias and Thrombosis\u201d of the European Society of Hypertension. J Hypertension. 2012;30(2):239\u201352.","journal-title":"J Hypertension"},{"issue":"5","key":"2580_CR20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.amjcard.2014.06.002","volume":"114","author":"AO Badheka","year":"2014","unstructured":"Badheka AO, Patel NJ, Grover PM, Shah N, Patel N, Singh V, Deshmukh AJ, Mehta K, Chothani A, Savani GT, et al. Optimal blood pressure in patients with atrial fibrillation (from the AFFIRM Trial). Am J Cardiol. 2014;114(5):727\u201336.","journal-title":"Am J Cardiol"},{"issue":"10","key":"2580_CR21","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.amjcard.2019.02.010","volume":"123","author":"S Vemulapalli","year":"2019","unstructured":"Vemulapalli S, Inohara T, Kim S, Thomas L, Piccini JP, Patel MR, Chang P, Fonarow GC, Ezekowitz MD, Hylek E, et al. Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry). Am J Cardiol. 2019;123(10):1628\u201336.","journal-title":"Am J Cardiol"},{"issue":"14","key":"2580_CR22","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","volume":"383","author":"P Kirchhof","year":"2020","unstructured":"Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, Fetsch T, van Gelder IC, Haase D, Haegeli LM, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305\u201316.","journal-title":"N Engl J Med"},{"issue":"16","key":"2580_CR23","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1056\/NEJMoa0805710","volume":"360","author":"M Disertori","year":"2009","unstructured":"Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale G, Tognoni G. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360(16):1606\u201317.","journal-title":"N Engl J Med"},{"issue":"10","key":"2580_CR24","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1056\/NEJMoa1008816","volume":"364","author":"S Yusuf","year":"2011","unstructured":"Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ. Irbesartan in patients with atrial fibrillation. N Engl J Med. 2011;364(10):928\u201338.","journal-title":"N Engl J Med"},{"issue":"1","key":"2580_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/CIRCEP.111.965178","volume":"5","author":"A Goette","year":"2012","unstructured":"Goette A, Sch\u00f6n N, Kirchhof P, Breithardt G, Fetsch T, H\u00e4usler KG, Klein HU, Steinbeck G, Wegscheider K, Meinertz T. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol. 2012;5(1):43\u201351.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"1","key":"2580_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40256-019-00353-5","volume":"20","author":"J Neefs","year":"2020","unstructured":"Neefs J, van den Berg NWE, Krul SPJ, Boekholdt SM, de Groot JR. Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial. Am J Cardiovasc Drugs: Drugs Devices Intervent. 2020;20(1):73\u201380.","journal-title":"Am J Cardiovasc Drugs: Drugs Devices Intervent"},{"issue":"5","key":"2580_CR27","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jacc.2004.06.080","volume":"45","author":"K Wachtell","year":"2005","unstructured":"Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahl\u00f6f B, Ibsen H, Julius S, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45(5):705\u201311.","journal-title":"J Am Coll Cardiol"},{"key":"2580_CR28","doi-asserted-by":"crossref","unstructured":"Cesp\u00f3n-Fern\u00e1ndez M, Raposeiras-Roub\u00edn S, Abu-Assi E, Melendo-Viu M, Garc\u00eda-Campo E, \u00cd\u00f1iguez-Romo A. Renin-angiotensin system inhibitors prognostic benefit in older patients with atrial fibrillation. J Am Med Direct Assoc. 2021.","DOI":"10.1016\/j.jamda.2021.01.063"},{"issue":"7","key":"2580_CR29","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.tcm.2017.05.002","volume":"27","author":"A G\u00f3mez-Outes","year":"2017","unstructured":"G\u00f3mez-Outes A, Su\u00e1rez-Gea ML, Garc\u00eda-Pinilla JM. Causes of death in atrial fibrillation: challenges and opportunities. Trends Cardiovasc Med. 2017;27(7):494\u2013503.","journal-title":"Trends Cardiovasc Med"},{"issue":"1","key":"2580_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/ehjqcco\/qcy033","volume":"5","author":"Y An","year":"2019","unstructured":"An Y, Ogawa H, Yamashita Y, Ishii M, Iguchi M, Masunaga N, Esato M, Tsuji H, Wada H, Hasegawa K, et al. Causes of death in Japanese patients with atrial fibrillation: The Fushimi Atrial Fibrillation Registry. Eur Heart J Qual Care Clin Outcomes. 2019;5(1):35\u201342.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2580_CR31","doi-asserted-by":"crossref","unstructured":"Hsu WT, Galm BP, Schrank G, Hsu TC, Lee SH, Park JY, Lee CC. Effect of renin-angiotensin-aldosterone system inhibitors on short-term mortality after sepsis: a population-based cohort study. Hypertension (Dallas, Tex: 1979) 2020, 75(2):483\u2013491.","DOI":"10.1161\/HYPERTENSIONAHA.119.13197"},{"key":"2580_CR32","doi-asserted-by":"publisher","first-page":"104927","DOI":"10.1016\/j.phrs.2020.104927","volume":"158","author":"X Zhang","year":"2020","unstructured":"Zhang X, Yu J, Pan LY, Jiang HY. ACEI\/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis. Pharmacol Res. 2020;158:104927.","journal-title":"Pharmacol Res"},{"issue":"12","key":"2580_CR33","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and Angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126(12):1671\u201381.","journal-title":"Circ Res"},{"key":"2580_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2466-5-12","volume":"5","author":"EM Mortensen","year":"2005","unstructured":"Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalized with community-acquired pneumonia. BMC Pulm Med. 2005;5:12.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"2580_CR35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jss.2013.08.004","volume":"186","author":"Y Hirano","year":"2014","unstructured":"Hirano Y, Takeuchi H, Suda K, Hagiwara T, Miyasho T, Kawamura Y, Yamada S, Oyama T, Takahashi T, Wada N, et al. (Pro)renin receptor blocker improves survival of rats with sepsis. J Surg Res. 2014;186(1):269\u201377.","journal-title":"J Surg Res"},{"issue":"11","key":"2580_CR36","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","volume":"14","author":"GYH Lip","year":"2017","unstructured":"Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. 2017;14(11):627\u20138.","journal-title":"Nat Rev Cardiol"},{"key":"2580_CR37","doi-asserted-by":"crossref","unstructured":"Romiti GF, Pastori D, Rivera-Caravaca JM, Ding WY, Gue YX, Menichelli D, Gumprecht J, Kozie\u0142 M, Yang PS, Guo Y et al: Adherence to the 'Atrial Fibrillation Better Care' pathway in patients with atrial fibrillation: impact on clinical outcomes-a systematic review and meta-analysis of 285,000 patients. Thrombosis Haemostasis 2021.","DOI":"10.1093\/europace\/euab116.290"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02580-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-022-02580-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02580-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T12:07:23Z","timestamp":1648814843000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-022-02580-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2580"],"URL":"https:\/\/doi.org\/10.1186\/s12872-022-02580-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1188151\/v1","asserted-by":"object"}]},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"assertion":[{"value":"20 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. The study was approved by ethics board of Fuwai Hospital (NO. 2012-428) and informed consent was taken from all individual participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}